Skip to main content
. 2020 Nov 6;124(3):587–594. doi: 10.1038/s41416-020-01140-9

Fig. 1. Survival times in the RASwt population (n = 400).

Fig. 1

Progression-free (a) and overall (b) survival in the RAS wild-type population (N = 400). Bev bevacizumab, Cet cetuximab.